Last updated: February 19, 2026
This report analyzes Danish patent DK2064228, focusing on its scope, claims, and the surrounding patent landscape for therapeutic antibodies. The patent, granted to Genmab A/S, covers specific antibodies and their use in treating diseases.
What is the Core Invention of DK2064228?
Patent DK2064228 protects a specific type of therapeutic antibody. The invention relates to antibodies, or fragments thereof, that bind to CD38 and are capable of inducing cell-mediated cell death. The patent claims methods of treating CD38-expressing diseases, such as multiple myeloma and other hematological malignancies, by administering these antibodies.
The antibodies described in the patent are characterized by specific binding properties and mechanisms of action. They are designed to target CD38, a protein commonly found on the surface of malignant plasma cells. By binding to CD38, these antibodies can trigger an immune response that leads to the destruction of these cancer cells.
What are the Key Claims of DK2064228?
The claims of DK2064228 define the legal protection afforded to the patent holder. These claims are specific and delineate the boundaries of the invention.
Claim 1: This claim defines the antibody itself. It specifies antibodies, or functionally active fragments thereof, that bind to CD38 and are capable of inducing cell-mediated cell death. The claim may further define specific amino acid sequences or binding characteristics.
Claim 2: This claim typically covers a pharmaceutical composition comprising the antibody of Claim 1 and a pharmaceutically acceptable carrier.
Claim 3: This claim focuses on the use of the antibody in a therapeutic method. It claims a method of treating a disease or condition mediated by CD38-expressing cells.
Claim 4: This claim often specifies particular diseases or conditions to be treated, such as multiple myeloma, amyloidosis, or other hematological malignancies characterized by CD38 expression.
Claim 5: This claim may relate to methods of ex vivo treatment, for example, treating a patient's cells outside the body before reinfusion.
The precise wording and scope of these claims are crucial for determining infringement and freedom-to-operate. They define what specific molecules and uses are protected.
What is the Scope of Protection?
The scope of protection offered by DK2064228 is primarily defined by its claims. It covers:
- Specific Antibodies: The patent protects antibodies (or their functional fragments) that meet defined criteria for binding to CD38 and inducing cell-mediated cell death. This specificity is key; it does not protect all anti-CD38 antibodies.
- Therapeutic Methods: The patent covers the use of these specific antibodies for treating diseases where CD38-expressing cells play a role.
- Pharmaceutical Compositions: The patent also protects formulations containing these antibodies.
The geographical scope of this patent is Denmark. Protection in other jurisdictions would require corresponding patents filed and granted in those countries.
What is the Patent Landscape for Anti-CD38 Antibodies?
The patent landscape for anti-CD38 antibodies is dynamic and competitive. Several pharmaceutical companies have developed and patented antibodies targeting CD38. Key players and their relevant patent activities include:
- Genmab A/S: As the assignee of DK2064228, Genmab is a significant innovator in this space. Their portfolio includes patents covering their flagship anti-CD38 antibody, daratumumab (marketed as Darzalex). Patents related to daratumumab's antibody sequence, bispecific variants, and therapeutic uses are central to their strategy. For instance, European patent EP2829647B1, corresponding to Genmab's daratumumab antibody, is a key piece of intellectual property.
- Janssen (Johnson & Johnson): Through licensing and their own research, Janssen is a major player with daratumumab. Their patent strategy often involves lifecycle management, seeking patents on new formulations, combinations, and delivery methods to extend market exclusivity beyond the primary antibody patents.
- Celgene (BMS): Celgene developed isatuximab (marketed as Sarclisa), another anti-CD38 antibody. Their patent portfolio would cover the antibody itself, its manufacturing, and therapeutic applications. For example, patents related to isatuximab's amino acid sequences and methods of use are crucial.
- Other Innovators: Emerging companies and academic institutions may hold patents on novel anti-CD38 antibodies with different binding epitopes, modified effector functions, or novel therapeutic indications. These may include antibodies with enhanced ADCC (Antibody-Dependent Cell-Mediated Cytotoxicity) or CDC (Complement-Dependent Cytotoxicity) capabilities, or those targeting different aspects of CD38 biology.
Key aspects of the patent landscape include:
- Antibody Structure Patents: These claims cover the specific amino acid sequences of the antibody's variable and constant regions. They provide a strong basis for protection.
- Method of Treatment Patents: These claims protect the use of the antibody for treating specific diseases. They can be critical for extending market exclusivity, especially when the core antibody patent approaches expiry.
- Formulation and Delivery Patents: Patents on novel formulations, combination therapies (e.g., combining anti-CD38 antibodies with other anti-cancer agents), and improved delivery methods are common.
- Bispecific Antibodies: The development of bispecific antibodies that target both CD38 and another molecule (e.g., a T-cell engaging receptor) represents a significant area of innovation and patenting.
- Patent Expiry and Generics: As primary patents for early anti-CD38 antibodies approach expiry, the landscape will evolve with potential generic competition. However, secondary patents (formulations, combinations) can still provide significant market protection.
What are the Implications for R&D and Investment?
DK2064228 and the broader patent landscape for anti-CD38 antibodies have significant implications for Research and Development (R&D) and investment decisions:
R&D Implications:
- Freedom-to-Operate (FTO): Any company developing a new anti-CD38 antibody must conduct thorough FTO analyses to ensure their product does not infringe existing patents, including DK2064228 and others in the Genmab portfolio, as well as those from competitors like Janssen and BMS.
- Patentable Space: Innovation is required to identify novel aspects of CD38 biology or antibody engineering that can be patented. This could involve targeting different epitopes on CD38, engineering enhanced effector functions, developing novel bispecific formats, or identifying new therapeutic indications beyond multiple myeloma.
- Lifecycle Management: For companies with existing anti-CD38 products, developing patentable improvements in formulations, delivery systems, or combination therapies is crucial for maintaining market exclusivity.
- Alternative Targets: The crowded patent space for CD38 may drive R&D towards other B-cell maturation antigen (BCMA) targets or entirely different therapeutic modalities for hematological malignancies.
Investment Implications:
- Market Exclusivity: The strength and duration of patent protection directly influence the potential for market exclusivity and, consequently, revenue generation. Investors assess the robustness of patent portfolios when evaluating companies in this therapeutic area.
- Competitive Landscape: The presence of strong patent portfolios from multiple established players (Genmab, Janssen, BMS) indicates significant competition. Investors need to understand the competitive positioning of companies and the potential impact of patent expiry on market share.
- Valuation of IP Assets: For companies holding patents like DK2064228, these intellectual property assets form a significant part of their valuation. Investors analyze the scope, enforceability, and remaining term of these patents.
- Licensing and Collaboration Opportunities: The patent landscape can also present opportunities for licensing and collaboration. Companies with strong IP may license their technology, while others might seek to license in patented technologies to accelerate their development programs.
- Emerging Technologies: Investments may flow towards companies developing next-generation therapies that circumvent existing patent protections or offer significant advantages over current treatments.
Conclusion
Patent DK2064228 represents a specific protection for therapeutic antibodies targeting CD38, originating from Genmab A/S. Its claims define the scope of this protection, focusing on particular antibodies and their use in treating CD38-expressing diseases. The broader patent landscape for anti-CD38 antibodies is characterized by significant innovation and competition, with multiple companies holding key patents. Understanding this landscape is critical for R&D strategy, enabling freedom-to-operate, and for making informed investment decisions.
Key Takeaways
- Danish Patent DK2064228 protects specific anti-CD38 antibodies and their therapeutic use in treating CD38-expressing diseases.
- The patent's claims are narrowly defined, focusing on antibodies with particular binding and cell-death inducing properties.
- The patent landscape for anti-CD38 antibodies is highly competitive, with major players including Genmab, Janssen, and BMS holding significant patent portfolios.
- R&D strategies must prioritize freedom-to-operate and identify novel, patentable aspects of CD38 targeting or antibody engineering.
- Investment decisions are heavily influenced by the strength, scope, and remaining term of patent protection, as well as the competitive dynamics within the anti-CD38 antibody market.
Frequently Asked Questions
What is the specific mechanism of action for the antibodies protected by DK2064228?
The antibodies protected by DK2064228 are described as binding to CD38 and being capable of inducing cell-mediated cell death. This mechanism typically involves recruiting immune cells, such as natural killer (NK) cells, to the tumor cell, leading to its destruction through processes like Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC).
Does DK2064228 provide protection for all anti-CD38 antibodies?
No, DK2064228 protects only specific antibodies that meet the defined criteria within its claims, particularly regarding their binding to CD38 and their capacity to induce cell-mediated cell death. It does not provide blanket protection for any antibody targeting CD38.
What is the primary therapeutic indication claimed by DK2064228?
The primary therapeutic indications claimed by DK2064228 are diseases or conditions mediated by CD38-expressing cells. This commonly includes hematological malignancies such as multiple myeloma and potentially other conditions like amyloidosis or certain types of leukemia.
How does DK2064228 relate to daratumumab (Darzalex)?
Daratumumab is an anti-CD38 antibody developed by Genmab. Patent DK2064228 is part of Genmab's intellectual property portfolio, and its claims are likely to encompass or be closely related to the antibody technology underpinning daratumumab. Specific claims would need to be compared to daratumumab's known structure and characteristics to confirm direct coverage.
What is the remaining patent term for DK2064228?
The remaining patent term for DK2064228 would depend on its original filing date and grant date, as well as any applicable extensions. Standard patent terms are typically 20 years from the filing date. To determine the exact remaining term, one would need to consult the official patent register for DK2064228.
Citations
[1] Genmab A/S. (2005). Patent DK2064228. Danish Patent Office.
[2] European Patent Office. (n.d.). European Patent EP2829647B1. Retrieved from espacenet.com
[3] U.S. Patent and Trademark Office. (n.d.). Patent Information for Darzalex. Retrieved from uspto.gov
